Rare diseases have well-known data problems: patient populations are small, families are geographically dispersed, clinical presentations can vary widely, and long-term natural-history studies are often limited or absent. Yet another part of the story receives less attention. For many conditions, useful information may already exist—in patient registries, clinical records, family-reported experiences, genetic-testing databases, and the accumulated knowledge of patient advocacy communities.

The challenge to improve data curation in rare disease is not simply to collect more information. It is asking the right questions of the information already available, honestly evaluating its limits, and bringing together the right partners to translate observations into evidence that can guide future research and clinical understanding.

This gap will be central to a forthcoming presentation by the Consortium for Understanding Research, and Education in X-linked NeuroDevelopmental Disorders (Cure NDD), BioLogic Pharma Solutions, and Northwestern University at the Child Neurology Society Annual Meeting, held October 14–17, 2026, in Montréal, Québec.

The collaborators will present an exploratory analysis of registry data from 43 people living with the ultra-rare neurodevelopmental disorder Coffin–Lowry syndrome, or CLS. The analysis examines how clinical symptoms and developmental milestones differ by sex when male and female data are considered separately rather than combined.

“Rare-disease organizations often spend years building something extraordinarily valuable: a community of patients and families willing to share their experiences,” shares Mary Hames, PhD, EMBA, CEO of BioLogic Pharma Solutions. “But collecting data and transforming it into evidence that can inform clinical care are two very different things. That translation requires a careful scientific process and genuine collaboration.”

When Averaging Obscures the Disease

CLS is associated with pathogenic variants in the RPS6KA3 gene and can affect neurodevelopment, cognition, skeletal health, growth, hearing, and physical function. The condition often presents more severely in males. Females, however, can experience a broad range of effects, from mild or subtle features to significant developmental and physical challenges.

That variability makes rare-disease evidence particularly difficult to interpret. When a small population is reported as a single group, important differences can be flattened into an “average” that does not fully describe either males or females.

A pooled dataset for an ultra-rare condition may be statistically convenient, but ignoring symptom variation by sex in X-linked conditions can leave clinicians, caregivers, researchers, and future therapy developers with an incomplete picture of when symptoms emerge, how disability progresses, and which forms of support may be needed.

The CLS analysis drew on registry-based information to examine clinical, neurologic, musculoskeletal, functional, and educational experiences. Rather than treating sex as a background demographic variable, the collaborators made it central to the analysis. Their rationale was straightforward: if the phenotype differs substantially by sex, aggregate reporting may fail to represent either group accurately.

The observations were exploratory, but potentially clinically meaningful. Males in the registry data showed substantially more spinal deformities. Wheelchair dependence occurred more often and, on average, about seven years earlier. Gastrointestinal symptoms appeared approximately 11.6 years earlier in males. The analysis also suggested differences in day-to-day functioning and educational needs, with males more likely to require intensive educational support and females showing greater functional independence.

Those findings do not establish a definitive natural history of CLS. They do, however, show why asking a more specific question can matter. For a clinician following a female patient with a less recognizable presentation, for a family planning support needs, or for a researcher considering outcomes worth measuring, the distinction between an average and a sex-stratified view of disease can be consequential.

The Bigger Question: Why It Wasn’t Seen Before

The analysis points to a broader structural gap in rare disease research. The question is not simply why sex-related differences in CLS had not been examined earlier. It is why so many registries, built through years of patient and family participation, struggle to become evidence that clinicians can discuss confidently, researchers can investigate further, and organizations can use to inform future research programs.

Advocacy organizations are often highly effective at finding patients who may otherwise remain invisible to the health system. They build trust with families, gather lived-experience information that may not appear in medical charts, maintain contact over time, and identify the practical questions that matter to a community.“Studies like this are incredibly important to Coffin-Lowry Syndrome (CLS) families navigating life alongside their loved ones with CLS,” commented Theresa Moxley, President of the Coffin-Lowry Syndrome Foundation. “We’re grateful to CLS researchers whose work helps deepen understanding and raise awareness of CLS.”

Academic and clinical collaborators add another essential layer. They bring methodological expertise, disease-specific knowledge, and clinical context to the research question. Their role is to assess whether a dataset can support an analysis, interpret patterns without overstating them, and identify what additional work is necessary before preliminary findings can influence clinical practice.

What may be missing is a translational layer between “we have a registry” and “we have evidence ready to be responsibly discussed with clinicians, researchers, industry, and, eventually, regulators.” That is where a modern medical-affairs function can play a larger role.

Advocacy Groups and Medical Affairs

Medical affairs is often defined through familiar activities: field medical science liaison deployment, advisory boards, congress planning, publications, and clinician education. While these functions are important, rare disease demands a broader view—one that begins earlier, when a potential evidence opportunity may still be difficult to recognize.

That process can begin with patient and community insights. It moves to a focused research question, an evaluation of the available dataset, analysis and scientific interpretation, and then to a poster, abstract, or manuscript. Findings can inform clinician education, expose gaps in current knowledge, and generate the next questions for prospective natural-history research or future clinical studies.

This process is intentionally iterative by design. Each stage can return collaborators to an earlier question: Are the data sufficiently complete? Is a pattern related to age, sex, genotype, or another factor? What do families report that a registry does not yet capture?

The collaboration among Cure NDD, BioLogic Pharma Solutions, and Northwestern University demonstrates what can happen when medical affairs enters the process as an active scientific partner rather than only as a communications function after the work is complete.

Cure NDD connects researchers, clinicians, patients and caregivers to advance treatments for X-linked neurodevelopmental disorders including CLS. Advocacy organizations such as Cure NDD can hold an unusually clear view of where diagnosis is delayed, which symptoms disrupt family life, what remains missing from the medical literature, and which questions patients most want answered.

Registry information in the CLS analysis allowed the team to examine clinical, neurologic, musculoskeletal, functional, and educational outcomes rather than limiting the analysis to one medical endpoint. That breadth of information is one strength of patient-driven datasets. It can help show how a rare condition affects health, independence, education, and family life at the same time.

Meanwhile, BioLogic Pharma Solutions’ role highlights its work with biotech and pharmaceutical organizations on physician engagement, clinical-trial site strategy, rare-disease diagnostic pathways, scientific communications, and pre-commercial planning. In this setting, they do not simply package findings after the fact; they help identify evidence opportunities, connect appropriate collaborators, and support a scientifically responsible path from community data to clinical discussion.

What Comes Next for CLS

For biotechnology companies entering a rare disease, the first question is often, “What evidence do we need to generate?” That question remains essential. Yet an equally useful starting point may be, “What evidence already exists, and what can we responsibly learn from it?” In rare disease, that can be the difference between starting from zero and building a more informed path forward.

Early medical-affairs work can identify existing registries, gaps in natural-history knowledge, diagnostic barriers, undercharacterized patient groups, overlooked phenotype differences, clinical-monitoring needs, endpoints worth investigating, publication opportunities, and questions that require prospective research. It can also identify where current information is insufficient to support conclusions—a valuable outcome when it helps direct future study toward the questions that matter most.

The sex-stratified observations in CLS are preliminary, but they establish a clear direction for future inquiry. The findings support further longitudinal study to understand how disease progression may differ over time and whether more tailored monitoring could help clinicians and families anticipate changing needs.

Potential next steps may include larger datasets, analyses that account for age and follow-up duration, deeper investigation of genotype–phenotype relationships, and exploration of X-inactivation as a possible contributor to variation among females. Peer-reviewed publication and clinician education may also be appropriate once the evidence base develops further. Each step necessitates guidance by the available data and priorities of the CLS community.

The future of rare-disease medical affairs is not only communicating evidence after it has been generated. It is increasingly about recognizing unanswered clinical questions, finding the right collaborators and datasets to investigate them, and helping turn responsible observations into evidence that can benefit patients.

Cure NDD, BioLogic Pharma Solutions, and Northwestern University’s Child Neurology Society presentation in Montréal is not a conclusion to the CLS research effort. It is an early, carefully qualified step in a longer process: beginning with a patient community’s willingness to share information, moving through rigorous scientific inquiry, and returning to the community, clinicians, and researchers with more focused questions, and ultimately building a more informed path forward.